Compare Adaptive Biotechnologies Corp (ADPT) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Zillow Group Inc Class C — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Zillow Group Inc Class C trades at $31.72 (market cap $7.50B). The key difference: Zillow Group Inc Class C is far larger — about 2.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| ADPT | Z | |
|---|---|---|
Market Cap | $3.33B | $7.50B |
Sector | Health | Media |
52-Week High | $22.37 | $90.35 |
52-Week Low | $10.24 | $29.41 |
Enterprise Value | $3.19B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Zillow Group (Z) trades at $32.96, down 1.41% on the day, amid mixed technical signals and ongoing class action lawsuits. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and net income turning positive at $23M, though valuation remains elevated with a P/E of 131.84. Analyst consensus is a Buy with a $63 price target, but legal overhangs and negative cash flow trends present headwinds.
The outlook is cautiously optimistic given strong revenue growth and analyst support, but investment opportunities are tempered by legal risks and high valuation multiples. Key risks include lawsuit outcomes, competitive pressures, and cash flow sustainability, requiring careful monitoring of upcoming Q2 2026 earnings on August 5 for confirmation of profit trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
